Can drug combinations improve upon monotherapy in HIV infection?

Abstract

It is not surprising that many patients with AIDS opt out of long-term treatment with combination therapy. They are faced with considerable adverse effects and currently cannot be assured that the combination will prolong their survival. This issue will be addressed by the Delta trial, which is well underway in several countries. Inpharma ® spoke with one of the investigators, Dr Michael Rawlinson, about the trial’s progress and considered the answers the trial should provide.